BeyondSpring says FDA grants Fast Track designation for plinabulin-docetaxel Phase 3 DUBLIN-4 NSCLC trial

• BeyondSpring won FDA Fast Track status for plinabulin with docetaxel in later-line advanced non-squamous NSCLC without actionable genomic alterations.
• The designation supports its ongoing global Phase 3 DUBLIN-4 study, which is designed to test whether the regimen can extend survival.
• No clinical results were presented; the next readout is planned at an interim analysis tied to disease-progression events.
• A China-focused deal shifts funding for about half of the trial’s 442 planned patients to an outside investor, reducing cash needs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeyondSpring Inc. published the original content used to generate this news brief on September 29, 2026, and is solely responsible for the information contained therein.